Clinical Trial Update: Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) [Phase 1]

View source ↗

Summary

Phase 1 trial of Vevorisertib (ARQ 751) as a single agent or with other anti-cancer agents in solid tumors with PIK3CA/AKT/PTEN mutations; terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Vevorisertib (ARQ 751)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer, Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2022-06-15